Editorial: felcisetrag-forward movement as a novel prokinetic for gastroparesis

Benjamin D Rogers^{1

2}, Gregory S Sayuk^{1

3}

Affiliations

¹ Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO, USA.
² Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville School of Medicine, Louisville, KY, USA.
³ St. Louis Veterans Affairs Medical Center, St. Louis, MO, USA.

Editorial

Benjamin D Rogers et al. Aliment Pharmacol Ther. 2021 May.

. 2021 May;53(10):1158-1159.

doi: 10.1111/apt.16334.

Benjamin D Rogers^{1

2}, Gregory S Sayuk^{1

3}

¹ Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO, USA.
² Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville School of Medicine, Louisville, KY, USA.
³ St. Louis Veterans Affairs Medical Center, St. Louis, MO, USA.

No abstract available

Comment on

Randomised study: effects of the 5-HT₄ receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis.
Chedid V, Brandler J, Arndt K, Vijayvargiya P, Wang XJ, Burton D, Harmsen WS, Siegelman J, Chen C, Chen Y, Almansa C, Dukes G, Camilleri M. Chedid V, et al. Aliment Pharmacol Ther. 2021 May;53(9):1010-1020. doi: 10.1111/apt.16304. Epub 2021 Mar 12. Aliment Pharmacol Ther. 2021. PMID: 33711180 Free PMC article. Clinical Trial.

1. Wiseman LR, Cisapride FD. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs. 1994;47:116-152.
1. Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35:745-767.
1. Chedid V, Brandler J, Arndt K, et al. Randomised study: effects of the 5-HT4 receptor agonist felcisetrag versus placebo on gut transit in patients with gastroparesis. Aliment Pharmacol Ther. 2021;53:1010-1020.
1. Beattie DT, Armstrong SR, Vickery RG, et al. The pharmacology of TD-8954, a potent and selective 5-HT(4) receptor agonist with gastrointestinal prokinetic properties. Front Pharmacol. 2011;2:25.
1. McKinnell RM, Armstrong SR, Beattie DT, et al. Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties. Bioorg Med Chem Lett. 2013;23:4210-4215.